Institut de Recherches Servier, of Paris, inked a nonexclusive collaboration to use the enhanced spine platform (ESP) technology developed by Afraxis Inc., of San Diego, to discover central nervous system (CNS) drugs

Institut de Recherches Servier, of Paris, inked a nonexclusive collaboration to use the enhanced spine platform (ESP) technology developed by Afraxis Inc., of San Diego, to discover central nervous system (CNS) drugs

In separate news, Astellas signed a deal to access the TSUBAME2.0 supercomputer at the Tokyo Institute of Technology to discover candidates for NTDs caused by dengue virus...In other news, The Nasdaq OMX Stockholm's listing committee approved the listing of NeuroVive's shares

GFAP and Nestin are proteins that are co-expressed by certain key cells found in the human central nervous system

UCB SA, of Brussels, Belgium and Five Prime Therapeutics Inc., of South San Francisco, both said that they have entered a strategic collaboration for the discovery of biologics targets and therapeutics in the areas of fibrosis-related inflammatory diseases and central nervous system disorders

Stem Cell Therapeutics Corp., of Toronto, inked a joint venture agreement with ReNeu Inc., of Calgary, Alberta, and NexGen Medical Systems Inc., of Melbourne, Fla., under which SCT and NexGen will license their respective technologies to ReNeu, a company formed to commercialize drug-based therapies to treat central nervous system disorders in combination with devices and processes for direct-to-brain administration

The two initially defined a wide range of fields, including metabolic diseases, central nervous system disorders, immunological diseases and cancer, in which they will jointly assess and potentially pursue assays, screens and models but in particular exploratory drug targets and compounds

The two initially defined a wide range of fields, including metabolic diseases, central nervous system disorders, immunological diseases and cancer, in which they will jointly assess and potentially pursue assays, screens and models but in particular exploratory drug targets and compounds

Under the 2010 collaboration, Genmab is tasked with creating human antibodies to three central nervous system targets identified by Lundbeck

Beactica AB, of Uppsala, Sweden, inked a research services agreement with Janssen Research and Development, a division of Janssen Pharmaceutica NV, of Beerse, Belgium, both divisions of Johnson & Johnson, to use its Sprint drug discovery platform to identify allosteric modulators of certain central nervous system proteins

Under the agreement, biOasis will carry out studies of the technology as it relates to UCB's central nervous system compounds

Beactica AB, of Uppsala, Sweden, inked a research services agreement with Janssen Research and Development, a division of Janssen Pharmaceutica NV, of Beerse, Belgium, to use its Sprint drug discovery platform to identify allosteric modulators of certain central nervous system proteins

Omeros Corp., of Seattle, said its GPR17-targeting compounds have been demonstrated to promote differentiation of the cells that form myelin in the central nervous system

Safety pharmacology studies also will be conducted to assess the effects of FluCide on the cardiovascular, respiratory and central nervous systems

ATTR is a rare, debilitating, hereditary disease that damages the nervous system and heart, resulting in a life expectancy of five to 15 years...Pfizer Inc., of New York, said it is buying NextWave Pharmaceuticals Inc., of Cupertino, Calif., a privately held specialty pharmaceutical company focused on the treatment of attention deficit/hyperactivity disorder (ADHD) and related central nervous system disorders

The results showed that NKTR-171 effectively blocks the inactivated state of sodium channel cells and in animal models of persistent neuropathic pain, NKTR-171 showed superior or comparable efficacy to gabapentin without generating the central nervous system side effects observed with current therapies used to treat neuropathic pain

The rodents treated with MultiStem displayed sustained and statistically significant improvement in functional testing compared to placebo-treated animals, correlating with a statistical decrease in demyelinated lesions in the nervous system of treated animals compared to placebo, as well as increased remyelination in treated animals...The companies will collaborate on a central nervous system target in order to explore the use of re-engineered antibodies to accelerate the blood-brain barrier (BBB

Rodents treated with MultiStem sustained statistically significant improvements in functional testing compared to placebo-treated animals, and those improvements correlated with statistical decreases in demyelinated lesions in the nervous system of treated animals, as well as increased remyelination

In 2004, the company entered a multiyear, multitarget drug discovery alliance with Boehringer to jointly identify and develop preclinical development candidates for the treatment of various disease areas, including central nervous system diseases, inflammation, cardiometabolic and respiratory diseases